Verified Nov 2026
Other
·

·
Since 1978
Hikma Pharmaceuticals is a British multinational pharmaceutical manufacturer founded in 1978, headquartered in London and employing 5,000–10,000 people. The company produces sterile injectable medicines, generic pharmaceuticals, and branded products across respiratory, oncology, pain management, and cardiovascular areas, serving hospitals and healthcare providers globally. In 2026, Hikma announced a $267 million investment in Ohio manufacturing facilities to expand capacity and create 350 jobs.
Hikma Pharmaceuticals at a glance
Revenue
$1-5B
Est. band
Employees
5,000-10,000
Founded
1978
Import activity
5478
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
5478
Named foreign suppliers
50
Top origins
Portugal · Germany · Morocco · Spain

Shared foreign counterparties do not establish that these companies buy from Hikma Pharmaceuticals.
What this tells a buyer
Hikma recorded 5,478 total shipments across customs records, with supply origins in Portugal (3,837 shipments), Switzerland (1,223 shipments), and Germany (515 shipments combined), alongside sourcing from India, China, and other regions.
The company operates 29 manufacturing plants and 9 R&D centers, producing sterile injectable generics, oral generics, and biosimilar biologics with focus on regulatory compliance and quality assurance across multiple therapeutic areas.
Hikma operates in three main business segments—Injectables, Generics, and Branded products—and ranks among sterile injectable manufacturers in the United States, serving thousands of hospitals and millions of patients worldwide.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
48 years in operation (founded 1978).
5,478 US import shipments on record.
Overview
Hikma Pharmaceuticals is a British multinational pharmaceutical manufacturer founded in 1978, headquartered in London and employing 5,000–10,000 people. The company produces sterile injectable medicines, generic pharmaceuticals, and branded products across respiratory, oncology, pain management, and cardiovascular areas, serving hospitals and healthcare providers globally. In 2026, Hikma announced a $267 million investment in Ohio manufacturing facilities to expand capacity and create 350 jobs.
At a glance
Attribute | Detail |
|---|---|
Founded | 1978 |
Employees | 5,000-10,000 |
Revenue | $1-5B (estimated) |
What Hikma Pharmaceuticals makes
The company operates 29 manufacturing plants and 9 R&D centers, producing sterile injectable generics, oral generics, and biosimilar biologics with focus on regulatory compliance and quality assurance across multiple therapeutic areas.
Products and capabilities described on the company's own site include Assembly (source: hikma.com).
Trade and customs footprint
Hikma recorded 5,478 total shipments across customs records, with supply origins in Portugal (3,837 shipments), Switzerland (1,223 shipments), and Germany (515 shipments combined), alongside sourcing from India, China, and other regions. US customs bill-of-lading records list 5478 inbound shipments across 50 foreign suppliers, with top origins including Portugal · Germany · Morocco · Spain.
Latest developments
2026-10-29 — Hikma launches NPH Otic Solution, USP Sterile in the US, in partnership with Orbicular | Hikma (hikma.com)
2026-06-09 — Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs - BioSpace (biospace.com)
2026-06-01 — Hikma Pharmaceuticals Announces Major Expansion in Ohio, (globenewswire.com)
2026-03-18 — Investing in manufacturing excellence at Hikma | Hikma (hikma.com)
2026-03-18 — Investing in strategic partnerships driving growth in the US and MENA | Hikma (hikma.com)
2025-11-19 — Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region | Hikma (hikma.com)
Facilities
Public sources reference the following locations:
Ohio — globenewswire.com
Columbus, Ohio — biospace.com
Company details
Hikma operates in three main business segments—Injectables, Generics, and Branded products—and ranks among sterile injectable manufacturers in the United States, serving thousands of hospitals and millions of patients worldwide. Hikma Pharmaceuticals was founded in 1978, and has an estimated 5,000-10,000 employees. On the LightSource stability read it is rated "Established & active": 48 years in operation (founded 1978). 5,478 US import shipments on record.
Frequently asked questions
What does Hikma Pharmaceuticals do?
Hikma Pharmaceuticals is a British multinational pharmaceutical manufacturer founded in 1978, headquartered in London and employing 5,000–10,000 people. The company produces sterile injectable medicines, generic pharmaceuticals, and branded products across respiratory, oncology, pain management, and cardiovascular areas, serving hospitals and healthcare providers globally. In 2026, Hikma announced a $267 million investment in Ohio manufacturing facilities to expand capacity and create 350 jobs.
When was Hikma Pharmaceuticals founded?
Hikma Pharmaceuticals was founded in 1978.
How big is Hikma Pharmaceuticals?
Hikma Pharmaceuticals has an estimated 5,000-10,000 employees, with revenue in the $1-5B range (estimated).
Does Hikma Pharmaceuticals import from overseas suppliers?
US customs bill-of-lading records show 5478 inbound shipments for Hikma Pharmaceuticals, with top origins including Portugal · Germany · Morocco · Spain.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
